Last
Update:
December 08, 2014
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
P Cahn, R Haubrich, J Leider, et al
Slide
Presentation
POSTER
Impact of baseline NNRTI mutations on the virological response to TMC125 in
the Phase III
clinical trials DUET-1 and DUET-2
J Vingerhoets, A Buelens, M Peeters, et al
PDF Poster
P Cahn, R Haubrich, J Leider, et al
Slide
Presentation
POSTER
Pharmacokinetics of TMC125 in once- and twice-daily regimens in HIV-1-negative
volunteers
M Schöller-Gyüre, TN Kakuda, G De Smedt, et al
PDF Poster
POSTER
Pharmacokinetics of TMC125 in HIV-negative volunteers with mild or moderate
hepatic impairment
M Schöller-Gyüre, TN Kakuda, G De Smedt, et al
PDF Poster
-
DUET-1: 24 week results of a phase III randomised double-blind trial to
evaluate the efficacy
and safety of TMC125 versus placebo in 612 treatment-experienced HIV-1
infected patients
Mills A, Cahn
P, Grinsztejn B, et al
Abstract
-
DUET-2: 24 week results of a phase III randomised double-blind trial to
evaluate the efficacy
and safety of TMC125 versus placebo in 591 treatment-experienced HIV-1
infected patients
Katlama C,
Campbell T, Clotet B, et al
Abstract
-
POSTER
Pharmacokinetic interaction between the non-nucleoside reverse transcriptase
inhibitor
(NNRTI) TMC125 and atorvastatin in HIV-negative volunteers
Schöller-Gyüre M, Kakuda TN, De Smedt G, et al
PDF Poster
Abstract-
HIV-1 NNRTI mutation profiles in clinical practice: implications for TMC125
use
Cotte L,
Trabaud M-A, Tardy J-C, et al
Abstract
-
POSTER
Pharmacokinetic evaluation of non-nucleoside reverse transcriptase inhibitor
(NNRTI) TMC125
and integrase inhibitor (InSTI) raltegravir (RAL) in healthy subjects
Anderson MS., Kakuda TN., Miller JL., et al
PDF Poster
Abstract
POSTER
Development of a list of mutations associated with NNRTI resistance for use in
clinical research
L Tambuyzer, J Vingerhoets, H Azijn, et al
PDF Poster
8th Int Congress on Drug Therapy in HIV
Infection
|
POSTER
No
effect of TMC125 on the pharmacokinetics of oral contraceptives
M Schöller-Gyüre, C Debroye, F Aharchi, et al
PDF Poster
Abstract
POSTER
No
frequent reporting of neurological or psychiatric events during TMC125
treatment
B Woodfall, G De Smedt, C Berckmans, et al
PDF Poster
Abstract
Impact of NNRTI and NRTI resistance on the response to the regimen
of TMC125 plus two NRTIs
in Study TMC125-C227
B Woodfall, J Vingerhoets, M Peeters, et al
Abstract
POSTER
Pharmacokinetics of TMC125, with atazanavir (ATV) and
atazanavir/ritonavir (ATV/r)
Schöller-Gyüre, B Woodfall, T De Marez, et al
PDF Poster
Abstract
14th Conference on Retroviruses and
Opportunistic
Infections |
Pharmacokinetics and Pharmacodynamics of TMC125 in HIV-infected Patients
with NNRTI and
PI Resistance: TMC125-C223
T Kakuda, M
Schöller-Gyüre, M Peeters, et al
PDF Poster
The American
Conference for the Treatment of HIV- 2007
|
TMC125 in Combination With Medications Commonly Used in HIV
Infection:
Summary of Drug-Drug Interactions
T Surles, M Schöller-Gyüre, RM
Hoetelmans, et al
PDF Poster
8th Int Congress on Drug Therapy in HIV
Infection
|
POSTER
No
effect of TMC125 on the pharmacokinetics of oral contraceptives
M Schöller-Gyüre, C Debroye, F Aharchi, et al
PDF Poster
Abstract
POSTER
No
frequent reporting of neurological or psychiatric events during TMC125
treatment
B Woodfall, G De Smedt, C Berckmans, et al
PDF Poster
Abstract
Impact of NNRTI and NRTI resistance on the response to the regimen
of TMC125 plus two NRTIs
in Study TMC125-C227
B Woodfall, J Vingerhoets, M Peeters, et al
Abstract
POSTER
Pharmacokinetics of TMC125, with atazanavir (ATV) and
atazanavir/ritonavir (ATV/r)
Schöller-Gyüre, B Woodfall, T De Marez, et al
PDF Poster
Abstract
|
XVI
International AIDS Conference
|
-
TMC125 bioavailability is not affected by ranitidine and omeprazole
M. Schöller-Gyüre, G. De Smedt, H. Vanaken, et al
Abstract
-
Combination of TMC114/ritonavir and TMC125 in patients with multidrug
resistant HIV
Montaner J., Harris M., Larsen G., et al
Abstract
-
Pharmacokinetic interaction study with TMC125 and TMC114/rtv in
HIV-negative volunteers
Kakuda T., Schöller-Gyüre M., Peeters M., et al
Abstract
-
Lack of interaction between TMC125 and methadone
Schöller-Gyüre M., Woodfall B., Vanaken H., et al
Abstract
-
Prediction of clinical benefits of TMC125 from treatment effects on CD4
counts and HIV RNA
Grossman H., Cohen C., Nadler J., et al
Abstract
-
Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125,
and impact of baseline
resistance on the virologic response in study TMC125-C223
Cohen C., Steinhart C., Ward D., et al
Abstract
|
M Schöller-Gyüre, C Debroye, B Woodfall, et al
PDF
Poster
POSTER
Pharmacokinetic interaction between TMC125 and rifabutin
M Schöller-Gyüre, B Woodfall,C Debroye, et al
PDF
Poster
M Schöller-Gyüre, C Debroye, B Woodfall, et al
PDF
Poster
POSTER
Pharmacokinetics of amprenavir and TMC125 in HIV-infected volunteers receiving
TMC125 with fosamprenavir/ritonavir
M Schöller-Gyüre, B Woodfall, S Bollen,
et al
PDF
Poster
|
Etravirine Conference Citations Archives B |
|
16th
Int HIV Drug Resistance Workshop
Conference
Archives -
C